TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months MonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPR...
New TALVEY® plus DARZALEX FASPRO® data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
